Korea Investment CORP Boosts Stake in Qiagen N.V. $QGEN

Korea Investment CORP increased its position in shares of Qiagen N.V. (NYSE:QGEN) by 222.7% during the second quarter, HoldingsChannel reports. The institutional investor owned 247,801 shares of the company’s stock after buying an additional 171,015 shares during the quarter. Korea Investment CORP’s holdings in Qiagen were worth $11,893,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. SVB Wealth LLC purchased a new stake in Qiagen during the 1st quarter valued at approximately $31,000. MAI Capital Management increased its holdings in shares of Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after purchasing an additional 849 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after purchasing an additional 796 shares during the period. Finally, Cullen Frost Bankers Inc. grew its position in Qiagen by 13,144.4% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after buying an additional 1,183 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on QGEN. Cowen reissued a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. UBS Group upped their price target on Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research report on Tuesday, November 25th. Barclays set a $53.00 target price on Qiagen and gave the company an “overweight” rating in a report on Thursday, October 2nd. Finally, Wall Street Zen upgraded Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Three investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $49.69.

Qiagen Stock Performance

Shares of QGEN stock opened at $47.75 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The firm has a market capitalization of $10.61 billion, a price-to-earnings ratio of 28.21, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64. Qiagen N.V. has a one year low of $37.63 and a one year high of $51.88. The company has a 50 day moving average price of $46.29 and a 200 day moving average price of $46.88.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, November 6th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.03. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. During the same quarter in the prior year, the company earned $0.57 EPS. The company’s revenue was up 6.2% on a year-over-year basis. Sell-side analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.